How a California biotech briefly tripled its value by hyping a Covid-19 ‘cure’

Jason Mast

Editor

Last week, a California biotech called Sorrento Therapeutics emailed reporters about the discovery of an “exceptionally potent antibody” for Covid-19. Then the CEO, Henry Ji …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

How a California biotech briefly tripled its value by hyping a Covid-19 ‘cure’

Jason Mast

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

How AI can address ongoing challenges in the life sciences industry

How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

How a California biotech briefly tripled its value by hyping a Covid-19 ‘cure’